155 research outputs found

    Notes on Mayfly Nymphs from Northeastern Minnesota Which Key to \u3ci\u3eStenonema Vicarium\u3c/i\u3e (Ephemeroptera: Heptageniidae)

    Get PDF
    (excerpt) A review of the literature indicates that Stenonema vicarium (Walker) adults have not been collected from northeastern Minnesota. However, mayfly nymphs which key to that species, based on the descriptions in Lewis (1974), have been collected from many streams in the area which are also inhabited by nymphs of the closely related species, Stenonema fuscum (Clemens)

    From customer understanding to product understanding: Collaboration with industrial lead users in a B2B context

    Full text link
    Product innovation will continue to play a strategic role for companies producing high-quality, functional products for customers in the process industries. In the future, creating improved or radically new products will necessitate not only the development of product concepts resting more on an applied research knowledge base but also collaboration with customers. LKAB is a world-leading producer of processed iron ore products for steelmaking. The development of next-generation pellet products in collaboration with lead users presented an opportunity for a single case study in a B2B context. Two customers for present products as well as a technology/equipment supplier were identified as lead users. Using a framework grounded in lead user development, the Quality Function Deployment methodology (adapted to process-industrial use) was used as the facilitating instrument. It is concluded that this modified system will constitute an improved integrated knowledge-based platform for the development of new product and process concepts. It isargued that this development approach could also be applied in other process-industrial sectors serving industrial customers in an open innovation perspective

    A search for W bb and W Higgs production in ppbar collisions at sqrt(s)=1.96 TeV

    Get PDF
    We present a search for W b \bar{b} production in p \bar{p} collisions at sqrt{s}=1.96 TeV in events containing one electron, an imbalance in transverse momentum, and two b-tagged jets. Using 174 pb-1 of integrated luminosity accumulated by the D0 experiment at the Fermilab Tevatron collider, and the standard-model description of such events, we set a 95% C.L. upper limit on W b \bar{b}productionof6.6pbforbquarkswithtransversemomentapTb>20GeVandbbˉseparationinpseudorapidityazimuthspaceDeltaRbb>0.75.Restrictingthesearchtooptimizedbbˉmassintervalsprovidesupperlimitson production of 6.6 pb for b quarks with transverse momenta p_T^b > 20 GeV and b \bar{b} separation in pseudorapidity-azimuth space Delta R_bb > 0.75. Restricting the search to optimized b \bar{b} mass intervals provides upper limits on WHproductionof9.0 production of 9.0-12.2pb,forHiggsbosonmassesof10512.2 pb, for Higgs-boson masses of 105-$135 GeV.Comment: 7 pages, 4 figures, 1 table, submitted to Physical Review Letter

    Search for R-parity violating supersymmetry via the LLE couplings lambda_{121}, lambda_{122} or lambda_{133} in ppbar collisions at sqrt(s)=1.96 TeV

    Get PDF
    A search for gaugino pair production with a trilepton signature in the framework of R-parity violating supersymmetry via the couplings lambda_121, lambda_122, or lambda_133 is presented. The data, corresponding to an integrated luminosity of L~360/pb, were collected from April 2002 to August 2004 with the D0 detector at the Fermilab Tevatron Collider, at a center-of-mass energy of sqrt(s)=1.96 TeV. This analysis considers final states with three charged leptons with the flavor combinations eel, mumul, and eetau (l=e or mu). No evidence for supersymmetry is found and limits at the 95% confidence level are set on the gaugino pair production cross section and lower bounds on the masses of the lightest neutralino and chargino are derived in two supersymmetric models.Comment: 9 pages, 4 figures (fig2 includes 3 subfigures

    Search for W' boson production in the W'->tb decay channel

    Get PDF
    We present a search for the production of a new heavy gauge boson W' that decays to a top quark and a bottom quark. We have analyzed 230 pb^{-1} of data collected with the Dzero detector at the Fermilab Tevatron collider at a center-of-mass energy of 1.96 TeV. No significant excess of events above the standard model expectation is found in any region of the final state invariant mass distribution. We set upper limits on the production cross section of W' bosons times branching ratio to top quarks at the 95% confidence level for several different W' boson masses. We exclude masses between 200 GeV and 610 GeV for a W' boson with standard-model-like couplings, between 200 GeV and 630 GeV for a W' boson with right-handed couplings that is allowed to decay to both leptons and quarks, and between 200 GeV and 670 GeV for a W' boson with right-handed couplings that is only allowed to decay to quarks.Comment: 9 pages, 6 figures, accepted by Phys. Lett.

    Measurement of the Lifetime Difference in the B_s^0 System

    Get PDF
    We present a study of the decay B_s^0 -> J/psi phi We obtain the CP-odd fraction in the final state at time zero, R_perp = 0.16 +/- 0.10 (stat) +/- 0.02 (syst), the average lifetime of the (B_s, B_sbar) system, tau (B_s^0) =1.39^{+0.13}_{-0.16} (stat) ^{+0.01}_{-0.02} (syst) ps, and the relative width difference between the heavy and light mass eigenstates, Delta Gamma/Gamma = (Gamma_L - Gamma_H)/Gamma =0.24^{+0.28}_{-0.38} (stat) ^{+0.03}_{-0.04} (syst). With the additional constraint from the world average of the B_s^0$lifetime measurements using semileptonic decays, we find tau (B_s^0)= 1.39 +/- 0.06 ~ps and Delta Gamma/\Gamma = 0.25^{+0.14}_{-0.15}. For the ratio of the B_s^0 and B^0 lifetimes we obtain tau(B_s^0)/tau(B^0)} = 0.91 +/- 0.09 (stat) +/- 0.003 (syst).Comment: submitted to Phys. Rev. Lett. FERMILAB-PUB-05-324-

    Search for Neutral Higgs Bosons Decaying to Tau Pairs in p-pbar Collisions at sqrt(s) = 1.96 TeV

    Full text link
    A search for the production of neutral Higgs bosons Phi decaying into tau^+tau^- final states in p-pbar collisions at a center-of-mass energy of 1.96 TeV is presented. The data, corresponding to an integrated luminosity of up to 348 pb^-1, were collected by the D0 experiment at the Fermilab Tevatron Collider. Since no excess compared to the expectation from standard model processes is found, limits on the production cross section times branching ratio are set. The results are combined with those obtained from the D0 search for Phi b(b) to b-bbar-b(bbar) and are interpreted in the minimal supersymmetric standard model.Comment: Version accpeted by Phys. Rev. Lett. (minor changes

    Search for right-handed W bosons in top quark decay

    Full text link
    We present a measurement of the fraction f+ of right-handed W bosons produced in top quark decays, based on a candidate sample of ttˉt\bar{t} events in the lepton+jets decay mode. These data correspond to an integrated luminosity of 230pb^-1, collected by the DO detector at the Fermilab Tevatron ppˉp\bar{p} Collider at sqrt(s)=1.96 TeV. We use a constrained fit to reconstruct the kinematics of the ttˉt\bar{t} and decay products, which allows for the measurement of the leptonic decay angle θ\theta^* for each event. By comparing the cosθ\cos\theta^* distribution from the data with those for the expected background and signal for various values of f+, we find f+=0.00+-0.13(stat)+-0.07(syst). This measurement is consistent with the standard model prediction of f+=3.6x10^-4.Comment: Submitted to Physical Review D Rapid Communications 7 pages, 3 figure

    A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer

    Get PDF
    CONTEXT: The optimum use of brachytherapy (BT) combined with external beam radiotherapy (EBRT) for localised/locally advanced prostate cancer (PCa) remains uncertain.OBJECTIVE: To perform a systematic review to determine the benefits and harms of EBRT-BT.EVIDENCE ACQUISITION: Ovid MEDLINE, Embase, and EBM Reviews-Cochrane Central Register of Controlled Trials databases were systematically searched for studies published between January 1, 2000 and June 7, 2022, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. Eligible studies compared low- or high-dose-rate EBRT-BT against EBRT ± androgen deprivation therapy (ADT) and/or radical prostatectomy (RP) ± postoperative radiotherapy (RP ± EBRT). The main outcomes were biochemical progression-free survival (bPFS), severe late genitourinary (GU)/gastrointestinal toxicity, metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS), at/beyond 5 yr. Risk of bias was assessed and confounding assessment was performed. A meta-analysis was performed for randomised controlled trials (RCTs).EVIDENCE SYNTHESIS: Seventy-three studies were included (two RCTs, seven prospective studies, and 64 retrospective studies). Most studies included participants with intermediate-or high-risk PCa. Most studies, including both RCTs, used ADT with EBRT-BT. Generally, EBRT-BT was associated with improved bPFS compared with EBRT, but similar MFS, CSS, and OS. A meta-analysis of the two RCTs showed superior bPFS with EBRT-BT (estimated fixed-effect hazard ratio [HR] 0.54 [95% confidence interval {CI} 0.40-0.72], p &lt; 0.001), with absolute improvements in bPFS at 5-6 yr of 4.9-16%. However, no difference was seen for MFS (HR 0.84 [95% CI 0.53-1.28], p = 0.4) or OS (HR 0.87 [95% CI 0.63-1.19], p = 0.4). Fewer studies examined RP ± EBRT. There is an increased risk of severe late GU toxicity, especially with low-dose-rate EBRT-BT, with some evidence of increased prevalence of severe GU toxicity at 5-6 yr of 6.4-7% across the two RCTs.CONCLUSIONS: EBRT-BT can be considered for unfavourable intermediate/high-risk localised/locally advanced PCa in patients with good urinary function, although the strength of this recommendation based on the European Association of Urology guideline methodology is weak given that it is based on improvements in biochemical control.PATIENT SUMMARY: We found good evidence that radiotherapy combined with brachytherapy keeps prostate cancer controlled for longer, but it could lead to worse urinary side effects than radiotherapy without brachytherapy, and its impact on cancer spread and patient survival is less clear.</p
    corecore